NYSE:CTLT - Catalent Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$39.08 -1.00 (-2.50 %)
(As of 05/23/2018 04:00 PM ET)
Previous Close$40.02
Today's Range$39.07 - $40.02
52-Week Range$33.42 - $47.87
Volume47,825 shs
Average Volume839,015 shs
Market Capitalization$5.39 billion
P/E Ratio29.69
Dividend YieldN/A
Beta1.53

About Catalent (NYSE:CTLT)

Catalent logoCatalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through three segments: Softgel Technologies, Drug Delivery Solutions, and Clinical Supply Services. The Softgel Technologies segment offers formulation, development, and manufacturing services for softgels, which are used in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, and unit-dose cosmetics. Its principal softgel technologies include traditional softgel capsules, as well as Vegicaps and OptiShell capsules. The Drug Delivery Solutions segment formulates, develops, and manufactures prescription, and consumer and animal health products using OptiMelt, OptiPact, OptiForm, and Zydis, as well as other proprietary and conventional drug delivery technologies, such as prefilled syringes; manufactures blow-fill seal unit dose consisting of ADVASEPT technology; develops biologic cell line, such as GPEx and SMARTag technologies; provides biologics; and offers analytical and bioanalytical development, and testing services. This segment also provides analytical chemical, and cell-based testing and scientific; stability testing; respiratory products formulation and manufacturing; micronization and particle engineering; regulatory consulting; and bioanalytical testing services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:CTLT
CUSIPN/A
Phone732-537-6200

Debt

Debt-to-Equity Ratio2.53
Current Ratio2.18
Quick Ratio1.78

Price-To-Earnings

Trailing P/E Ratio29.69
Forward P/E Ratio25.21
P/E Growth2.14

Sales & Book Value

Annual Sales$2.08 billion
Price / Sales2.51
Cash Flow$2.51 per share
Price / Cash15.57
Book Value$8.01 per share
Price / Book4.88

Profitability

EPS (Most Recent Fiscal Year)$1.35
Net Income$109.80 million
Net Margins2.62%
Return on Equity21.76%
Return on Assets5.16%

Miscellaneous

Employees10,800
Outstanding Shares133,370,000

Catalent (NYSE:CTLT) Frequently Asked Questions

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How were Catalent's earnings last quarter?

Catalent (NYSE:CTLT) released its earnings results on Tuesday, May, 1st. The company reported $0.41 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.06. The business had revenue of $627.90 million for the quarter, compared to the consensus estimate of $610.47 million. Catalent had a return on equity of 21.76% and a net margin of 2.62%. The business's quarterly revenue was up 17.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.38 earnings per share. View Catalent's Earnings History.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY18 earnings guidance on Tuesday, May, 1st. The company provided earnings per share guidance of $1.57-$1.74 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.67. The company issued revenue guidance of $2.42-$2.48 billion, compared to the consensus revenue estimate of $2.45 billion.

What price target have analysts set for CTLT?

14 analysts have issued 12 month price objectives for Catalent's shares. Their predictions range from $38.00 to $50.00. On average, they anticipate Catalent's stock price to reach $45.8182 in the next twelve months. View Analyst Ratings for Catalent.

Who are some of Catalent's key competitors?

Who are Catalent's key executives?

Catalent's management team includes the folowing people:
  • Mr. John R. Chiminski, Chairman, Pres & CEO (Age 54)
  • Mr. Steven L. Fasman Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 55)
  • Mr. William Downie, Sr. VP of Global Marketing & Sales (Age 51)
  • Mr. Barry B. Littlejohns, Pres of Biologics & Specialty Drug Delivery (Age 52)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 46)

Has Catalent been receiving favorable news coverage?

Media coverage about CTLT stock has trended positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Catalent earned a coverage optimism score of 0.40 on Accern's scale. They also gave media coverage about the company an impact score of 47.09 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

Who are Catalent's major shareholders?

Catalent's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.45%), JPMorgan Chase & Co. (3.21%), Champlain Investment Partners LLC (2.72%), American Century Companies Inc. (2.15%), Earnest Partners LLC (1.90%) and Northern Trust Corp (1.52%). Company insiders that own Catalent stock include Blackstone Management Associat, Christine Dolan, Donald E Morel, Jr, John R Chiminski, Matthew M Walsh, Sharon Johnson, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.

Which institutional investors are selling Catalent stock?

CTLT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, BNP Paribas Arbitrage SA, Hood River Capital Management LLC, Dimensional Fund Advisors LP, JPMorgan Chase & Co., Loomis Sayles & Co. L P and Carillon Tower Advisers Inc.. Company insiders that have sold Catalent company stock in the last year include Christine Dolan, John R Chiminski and William Downie. View Insider Buying and Selling for Catalent.

Which institutional investors are buying Catalent stock?

CTLT stock was acquired by a variety of institutional investors in the last quarter, including Champlain Investment Partners LLC, Wells Fargo & Company MN, Prudential Financial Inc., GW&K Investment Management LLC, Impax Asset Management LLC, American Century Companies Inc., Segall Bryant & Hamill LLC and Mackay Shields LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $39.08.

How big of a company is Catalent?

Catalent has a market capitalization of $5.39 billion and generates $2.08 billion in revenue each year. The company earns $109.80 million in net income (profit) each year or $1.35 on an earnings per share basis. Catalent employs 10,800 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


MarketBeat Community Rating for Catalent (CTLT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  464
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Catalent (NYSE:CTLT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
14 Wall Street analysts have issued ratings and price targets for Catalent in the last 12 months. Their average twelve-month price target is $45.8182, suggesting that the stock has a possible upside of 17.24%. The high price target for CTLT is $50.00 and the low price target for CTLT is $38.00. There are currently 4 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.712.732.672.67
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $45.8182$45.8182$45.3333$41.3750
Price Target Upside: 17.24% upside15.44% upside6.24% upside3.36% upside

Catalent (NYSE:CTLT) Consensus Price Target History

Price Target History for Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2018KeyCorpUpgradeSector Weight ➝ Overweight$48.00MediumView Rating Details
3/21/2018Raymond JamesUpgradeMarket Perform ➝ Outperform$48.00HighView Rating Details
3/21/2018UBSUpgradeMarket Perform ➝ OutperformHighView Rating Details
2/6/2018Bank of AmericaBoost Price TargetBuy ➝ Buy$47.00 ➝ $49.00MediumView Rating Details
2/6/2018StephensDowngradeOverweight ➝ Equal WeightHighView Rating Details
2/5/2018Royal Bank of CanadaSet Price TargetBuy$48.00HighView Rating Details
1/24/2018Goldman Sachs GroupInitiated CoverageBuy$50.00HighView Rating Details
1/5/2018First AnalysisInitiated CoverageEqual WeightLowView Rating Details
11/7/2017Piper Jaffray CompaniesBoost Price TargetOverweight$45.00 ➝ $50.00N/AView Rating Details
10/23/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
9/21/2017Morgan StanleyUpgradeEqual Weight ➝ Overweight$29.00 ➝ $48.00HighView Rating Details
9/20/2017Wells Fargo & CoBoost Price TargetOutperform$39.00 ➝ $43.00LowView Rating Details
8/29/2017William BlairReiterated RatingOurperformHighView Rating Details
8/29/2017Jefferies GroupReiterated RatingHold$35.00 ➝ $38.00HighView Rating Details
8/29/2017JPMorgan Chase & Co.Reiterated RatingBuy$40.00HighView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Catalent (NYSE:CTLT) Earnings History and Estimates Chart

Earnings by Quarter for Catalent (NYSE:CTLT)

Catalent (NYSE:CTLT) Earnings Estimates

2018 EPS Consensus Estimate: $1.20
2019 EPS Consensus Estimate: $1.82
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20181$0.29$0.29$0.29
Q3 20182$0.36$0.36$0.36
Q4 20182$0.54$0.55$0.55
Q1 20191$0.26$0.26$0.26
Q2 20192$0.44$0.48$0.46
Q3 20192$0.42$0.45$0.44
Q4 20191$0.66$0.66$0.66

Catalent (NYSE CTLT) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018Q3 2018$0.35$0.41$610.47 million$627.90 millionViewN/AView Earnings Details
2/5/2018Q2 2018$0.31$0.41$565.05 million$606.30 millionViewN/AView Earnings Details
11/6/2017Q1 2018$0.20$0.21$490.75 million$543.90 millionViewN/AView Earnings Details
8/28/2017Q4 2017$0.57$0.65$547.48 million$616.90 millionViewN/AView Earnings Details
5/4/2017Q3 2017$0.36$0.38$470.95 million$532.60 millionViewListenView Earnings Details
2/6/2017Q217$0.27$0.27$474.07 million$483.70 millionViewListenView Earnings Details
11/7/2016Q117$0.13$0.16$430.26 million$442.20 millionViewListenView Earnings Details
8/29/2016Q416$0.53$0.52$498.06 million$532.20 millionViewListenView Earnings Details
5/4/2016Q316$0.31$0.20$425.92 million$438.00 millionViewN/AView Earnings Details
2/9/2016Q216$0.34$0.36$441.99 million$454.90 millionViewN/AView Earnings Details
11/3/2015Q116$0.21$0.14$407.80 million$423.00 millionViewN/AView Earnings Details
9/2/2015Q415$0.58$0.60$496.91 million$510.10 millionViewN/AView Earnings Details
5/5/2015Q3 2015$0.43$0.46$453.25 million$446.60 millionViewN/AView Earnings Details
2/11/2015Q215$0.33$0.44$451.40 million$455.80 millionViewN/AView Earnings Details
11/13/2014Q314$0.20$0.13$411.20 million$418.30 millionViewN/AView Earnings Details
9/4/2014Q4 2014$1.03$519.60 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Catalent (NYSE:CTLT) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Catalent (NYSE CTLT) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.70%
Institutional Ownership Percentage: 99.28%
Insider Trading History for Catalent (NYSE:CTLT)
Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Catalent (NYSE CTLT) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/8/2018William DownieSVPSell9,082$41.80$379,627.6046,986View SEC Filing  
12/12/2017John R ChiminskiInsiderSell181,458$39.62$7,189,365.96View SEC Filing  
11/21/2017Uwe RoehrhoffDirectorBuy7,500$39.22$294,150.00View SEC Filing  
8/29/2017Christine DolanSVPSell1,594$38.75$61,767.50View SEC Filing  
8/1/2017Christine DolanSVPSell745$34.85$25,963.25View SEC Filing  
4/25/2017Sharon JohnsonInsiderSell9,160$29.00$265,640.00View SEC Filing  
3/20/2017John R. ChiminskiInsiderSell73,819$28.62$2,112,699.78View SEC Filing  
2/15/2017Donald E. Morel, Jr.DirectorBuy10,000$29.27$292,700.00View SEC Filing  
9/9/2016Blackstone Management AssociatMajor ShareholderSell17,100,705$23.58$403,234,623.90View SEC Filing  
6/9/2016Blackstone Management AssociatMajor ShareholderSell8,785,539$24.51$215,333,560.89View SEC Filing  
5/27/2016Matthew M WalshInsiderSell21,197$28.85$611,533.45105,688View SEC Filing  
8/19/2015John R ChiminskiInsiderSell38,505$33.81$1,301,854.05View SEC Filing  
8/17/2015John R ChiminskiInsiderSell35,550$33.80$1,201,590.00View SEC Filing  
7/20/2015John R ChiminskiInsiderSell33,081$29.40$972,581.40View SEC Filing  
7/6/2015John R ChiminskiInsiderSell33,828$29.34$992,513.52View SEC Filing  
6/11/2015Blackstone Management AssociatMajor ShareholderSell1,844,963$28.13$51,898,809.19View SEC Filing  
6/8/2015Blackstone Management AssociatMajor ShareholderSell12,299,753$28.13$345,992,051.89View SEC Filing  
4/1/2015Scott HoultonInsiderSell16,253$30.61$497,504.33View SEC Filing  
3/27/2015Stephen LeonardInsiderSell31,005$30.13$934,180.65View SEC Filing  
2/17/2015Scott HoultonInsiderSell14,538$27.50$399,795.00View SEC Filing  
2/13/2015Scott HoultonInsiderSell1,400$28.28$39,592.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Catalent (NYSE CTLT) News Headlines

Source:
DateHeadline
Tenant on former Marion Labs campus completes $5.5M expansionTenant on former Marion Labs campus completes $5.5M expansion
finance.yahoo.com - May 22 at 4:37 PM
Catalent (CTLT) Receives Consensus Rating of "Buy" from BrokeragesCatalent (CTLT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 20 at 11:31 AM
Wired News – Zomedica Inks Deal with Seraph to Develop and Market Seraph’s Novel Pathogen Detection System for VeterinariansWired News – Zomedica Inks Deal with Seraph to Develop and Market Seraph’s Novel Pathogen Detection System for Veterinarians
finance.yahoo.com - May 14 at 9:47 AM
 Brokerages Expect Catalent (CTLT) Will Post Quarterly Sales of $690.52 Million Brokerages Expect Catalent (CTLT) Will Post Quarterly Sales of $690.52 Million
www.americanbankingnews.com - May 13 at 4:55 AM
Catalent (CTLT) Expected to Post Earnings of $0.60 Per ShareCatalent (CTLT) Expected to Post Earnings of $0.60 Per Share
www.americanbankingnews.com - May 11 at 5:16 AM
Catalent (CTLT) Rating Increased to Buy at Zacks Investment ResearchCatalent (CTLT) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - May 10 at 8:41 PM
Catalent, Inc. to Present at Four Upcoming Investor ConferencesCatalent, Inc. to Present at Four Upcoming Investor Conferences
finance.yahoo.com - May 9 at 4:48 PM
Catalent (CTLT) Forecasted to Earn Q3 2019 Earnings of $0.45 Per ShareCatalent (CTLT) Forecasted to Earn Q3 2019 Earnings of $0.45 Per Share
www.americanbankingnews.com - May 3 at 9:57 AM
Edited Transcript of CTLT earnings conference call or presentation 1-May-18 12:15pm GMTEdited Transcript of CTLT earnings conference call or presentation 1-May-18 12:15pm GMT
finance.yahoo.com - May 2 at 9:06 AM
Catalent (CTLT) Announces Quarterly  Earnings Results, Beats Estimates By $0.02 EPSCatalent (CTLT) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
www.americanbankingnews.com - May 1 at 4:14 PM
Catalent (CTLT) Releases FY18 Earnings GuidanceCatalent (CTLT) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 1 at 9:36 AM
BRIEF-Catalent Reports Q3 Earnings Per Share Of $0.14BRIEF-Catalent Reports Q3 Earnings Per Share Of $0.14
www.reuters.com - May 1 at 9:09 AM
Catalent Q3 Earnings OutlookCatalent Q3 Earnings Outlook
finance.yahoo.com - May 1 at 9:09 AM
Catalent beats by $0.02, beats on revenueCatalent beats by $0.02, beats on revenue
seekingalpha.com - May 1 at 9:09 AM
Catalent: Fiscal 3Q Earnings SnapshotCatalent: Fiscal 3Q Earnings Snapshot
finance.yahoo.com - May 1 at 9:09 AM
Catalent (CTLT) Receives Average Rating of "Buy" from BrokeragesCatalent (CTLT) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 25 at 11:19 AM
Catalent (CTLT) Scheduled to Post Earnings on WednesdayCatalent (CTLT) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 25 at 2:56 AM
Zacks: Brokerages Anticipate Catalent (CTLT) Will Post Quarterly Sales of $610.64 MillionZacks: Brokerages Anticipate Catalent (CTLT) Will Post Quarterly Sales of $610.64 Million
www.americanbankingnews.com - April 25 at 2:12 AM
 Analysts Expect Catalent (CTLT) Will Post Earnings of $0.39 Per Share Analysts Expect Catalent (CTLT) Will Post Earnings of $0.39 Per Share
www.americanbankingnews.com - April 23 at 9:20 PM
Catalent (CTLT) Lowered to "Buy" at BidaskClubCatalent (CTLT) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - April 20 at 12:41 PM
Catalent, Inc. Announces Third Quarter Fiscal Year 2018 Earnings Conference WebcastCatalent, Inc. Announces Third Quarter Fiscal Year 2018 Earnings Conference Webcast
finance.yahoo.com - April 16 at 4:41 PM
Catalent (CTLT) Stock Rating Lowered by BidaskClubCatalent (CTLT) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 14 at 5:51 PM
Catalent (CTLT) Rating Reiterated by Piper JaffrayCatalent (CTLT) Rating Reiterated by Piper Jaffray
www.americanbankingnews.com - April 9 at 8:06 PM
Catalent (CTLT) Stock Rating Lowered by ValuEngineCatalent (CTLT) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 8 at 12:54 PM
$610.64 Million in Sales Expected for Catalent (CTLT) This Quarter$610.64 Million in Sales Expected for Catalent (CTLT) This Quarter
www.americanbankingnews.com - April 8 at 1:52 AM
 Analysts Expect Catalent (CTLT) Will Announce Earnings of $0.39 Per Share Analysts Expect Catalent (CTLT) Will Announce Earnings of $0.39 Per Share
www.americanbankingnews.com - April 6 at 11:22 PM
Catalent (CTLT) Lifted to Buy at Zacks Investment ResearchCatalent (CTLT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - April 6 at 8:10 PM
Why Amicus Therapeutics Stock Rose in the Week Ended March 29Why Amicus Therapeutics Stock Rose in the Week Ended March 29
finance.yahoo.com - April 3 at 4:46 PM
Catalent (CTLT) Given Consensus Recommendation of "Buy" by AnalystsCatalent (CTLT) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - March 31 at 11:34 AM
Analysts Set Expectations for Catalents Q3 2018 Earnings (CTLT)Analysts Set Expectations for Catalent's Q3 2018 Earnings (CTLT)
www.americanbankingnews.com - March 30 at 7:04 AM
Uniquely Positioned Catalent Notches KeyBanc Upgrade'Uniquely Positioned' Catalent Notches KeyBanc Upgrade
finance.yahoo.com - March 28 at 4:41 PM
KeyBanc Upgrades Catalent (CTLT) to OverweightKeyBanc Upgrades Catalent (CTLT) to Overweight
www.streetinsider.com - March 28 at 9:22 AM
Catalent (CTLT) Lifted to "Overweight" at KeyCorpCatalent (CTLT) Lifted to "Overweight" at KeyCorp
www.americanbankingnews.com - March 28 at 8:05 AM
Catalent (CTLT) Upgraded to "Buy" by ValuEngineCatalent (CTLT) Upgraded to "Buy" by ValuEngine
www.americanbankingnews.com - March 25 at 11:21 AM
Raymond James Projects Rising Momentum At Catalent Driven By Biologics ExpansionRaymond James Projects 'Rising Momentum' At Catalent Driven By Biologics Expansion
finance.yahoo.com - March 22 at 9:21 AM
Catalent (CTLT) Expected to Post Quarterly Sales of $609.36 MillionCatalent (CTLT) Expected to Post Quarterly Sales of $609.36 Million
www.americanbankingnews.com - March 22 at 2:28 AM
Catalent (CTLT) Rating Increased to Outperform at UBSCatalent (CTLT) Rating Increased to Outperform at UBS
www.americanbankingnews.com - March 21 at 6:40 PM
Raymond James Projects Rising Momentum At Catalent Driven By Biologics Expansion - BenzingaRaymond James Projects 'Rising Momentum' At Catalent Driven By Biologics Expansion - Benzinga
www.benzinga.com - March 21 at 4:56 PM
Raymond James Financial Upgrades Catalent (CTLT) to "Outperform"Raymond James Financial Upgrades Catalent (CTLT) to "Outperform"
www.americanbankingnews.com - March 21 at 3:27 PM
Catalent (CTLT) Downgraded to "Hold" at Zacks Investment ResearchCatalent (CTLT) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 20 at 9:22 PM
Reviewing Catalent (CTLT) & Histogenics (HSGX)Reviewing Catalent (CTLT) & Histogenics (HSGX)
www.americanbankingnews.com - March 14 at 2:07 PM
Insider Selling: Catalent Inc (CTLT) SVP Sells 9,082 Shares of StockInsider Selling: Catalent Inc (CTLT) SVP Sells 9,082 Shares of Stock
www.americanbankingnews.com - March 12 at 1:29 PM
Catalent (CTLT) Downgraded by Zacks Investment ResearchCatalent (CTLT) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 9 at 9:40 PM
Catalent (CTLT) Upgraded to Buy at Zacks Investment ResearchCatalent (CTLT) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - March 8 at 8:48 PM
Biohaven (BHVN) Reports 1st Enrolled Patient in Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODTBiohaven (BHVN) Reports 1st Enrolled Patient in Phase 3 Clinical Trial To Evaluate Rimegepant Zydis ODT
www.streetinsider.com - March 7 at 9:15 AM
Wells Fargo & Company MN Has $29.47 Million Holdings in Catalent Inc (CTLT)Wells Fargo & Company MN Has $29.47 Million Holdings in Catalent Inc (CTLT)
www.americanbankingnews.com - March 6 at 3:09 PM
Catalent Inc (CTLT) Given Consensus Recommendation of "Buy" by BrokeragesCatalent Inc (CTLT) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 6 at 11:44 AM
Biohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of MigraineBiohaven Enrolls First Patient In Phase 3 Clinical Trial To Evaluate Rimegepant Zydis® ODT In The Acute Treatment Of Migraine
finance.yahoo.com - March 6 at 9:00 AM
Bank of New York Mellon Corp Purchases 64,561 Shares of Catalent Inc (CTLT)Bank of New York Mellon Corp Purchases 64,561 Shares of Catalent Inc (CTLT)
www.americanbankingnews.com - March 5 at 5:00 AM
Allianz Asset Management GmbH Has $29.12 Million Position in Catalent Inc (CTLT)Allianz Asset Management GmbH Has $29.12 Million Position in Catalent Inc (CTLT)
www.americanbankingnews.com - March 5 at 4:12 AM

SEC Filings

Catalent (NYSE:CTLT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Catalent (NYSE:CTLT) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Catalent (NYSE CTLT) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.